Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Cited In for PubMed (Select 14578243)

1.

Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.

Liebl A, Khunti K, Orozco-Beltran D, Yale JF.

Clin Med Insights Endocrinol Diabetes. 2015 Mar 24;8:13-9. doi: 10.4137/CMED.S20906. eCollection 2015. Review.

2.

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes.

Kim JH, Ahn JH, Kim SK, Lee DH, Kim HS, Shon HS, Jeon HJ, Kim TH, Cho YW, Kim JT, Han SM, Chung CH, Ryu OH, Lee JM, Lee SH, Kwon MJ, Kim TK, Namgoong IS, Kim ES, Jung IK, Moon SD, Han JH, Kim CH, Cho EH, Kim KY, Park HB, Lee KS, Lee SW, Lee SC, Kang CM, Jeon BS, Song MS, Yun SB, Chung HK, Seong JH, Jeong JY, Cha BY.

J Diabetes Investig. 2015 Mar;6(2):219-26. doi: 10.1111/jdi.12261. Epub 2014 Aug 6.

3.
4.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators.

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

5.

Population targeting and durability of multimorbidity collaborative care management.

Lin EH, Von Korff M, Peterson D, Ludman EJ, Ciechanowski P, Katon W.

Am J Manag Care. 2014 Nov;20(11):887-95.

6.

Modern basal insulin analogs: An incomplete story.

Singh AK, Gangopadhyay KK.

Indian J Endocrinol Metab. 2014 Nov;18(6):784-93. doi: 10.4103/2230-8210.140239. Review.

7.

Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy.

Simon AC, Gude WT, Holleman F, Hoekstra JB, Peek N.

J Med Internet Res. 2014 Oct 23;16(10):e235. doi: 10.2196/jmir.3198.

8.

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.

Fournier M, Germe M, Theobald K, Scholz GH, Lehmacher W.

Ger Med Sci. 2014 Oct 16;12:Doc14. doi: 10.3205/000199. eCollection 2014.

10.

Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations.

Reznik Y, Huang S; OpT2mise Study Group.

Diabetes Technol Ther. 2014 Nov;16(11):816-8. doi: 10.1089/dia.2014.0261. Epub 2014 Sep 5. No abstract available.

11.

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

Vora J, Christensen T, Rana A, Bain SC.

Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.

12.

Identifying and meeting the challenges of insulin therapy in type 2 diabetes.

Sorli C, Heile MK.

J Multidiscip Healthc. 2014 Jul 2;7:267-82. doi: 10.2147/JMDH.S64084. eCollection 2014. Review.

13.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.

14.

The evolution of insulin glargine and its continuing contribution to diabetes care.

Hilgenfeld R, Seipke G, Berchtold H, Owens DR.

Drugs. 2014 Jun;74(8):911-27. doi: 10.1007/s40265-014-0226-4.

15.

Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses.

Bi Y, Li X, Yang D, Hao Y, Liang H, Zhu D, Weng J.

J Diabetes Investig. 2012 Jun 6;3(3):283-93. doi: 10.1111/j.2040-1124.2011.00187.x.

16.

Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.

Fujita N, Tsujii S, Kuwata H, Kurokawa R, Matsunaga S, Okamura S, Mashitani T, Furuya M, Kitatani M, Ishii H.

J Diabetes Investig. 2012 Mar 28;3(2):164-9. doi: 10.1111/j.2040-1124.2011.00164.x.

17.

Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study.

Narita T, Goto T, Suganuma Y, Hosoba M, Morii T, Sato T, Fujita H, Miura T, Shimotomai T, Yamada Y, Kakei M.

J Diabetes Investig. 2011 Jan 24;2(1):63-70. doi: 10.1111/j.2040-1124.2010.00062.x.

18.

Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes.

Yamashiro K, Ikeda F, Fujitani Y, Watada H, Kawamori R, Hirose T.

J Diabetes Investig. 2010 Aug 2;1(4):149-53. doi: 10.1111/j.2040-1124.2010.00025.x.

19.

Treat-to-target trials in diabetes.

Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK.

Indian J Endocrinol Metab. 2014 Mar;18(2):166-74. doi: 10.4103/2230-8210.129106. Review.

20.

Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes.

Zhang Y, Xie YJ, Meng DD, Zhang HH, Chen H, Liu E.

Diabetol Metab Syndr. 2014 Mar 13;6(1):37. doi: 10.1186/1758-5996-6-37.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk